PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media278979ArticlesСтатьиDABIGATRAN: PROSPECTS FOR CLINICAL APPLICATIONДАБИГАТРАН: ПЕРСПЕКТИВЫ КЛИНИЧЕСКОГО ПРИМЕНЕНИЯZateyshchikovDmitriy AleksandrovichЗатейщиковДмитрий Александрович

ФГУ Учебно-научный медицинский центр УД Президента РФ

ZotovaIrina VyacheslavovnaЗотоваИрина Вячеславовна

ФГУ Учебно-научный медицинский центр УД Президента РФ

ZateyshcikovD AZotovaI VФГУ Учебно-научный медицинский центр УД Президента РФ150820111815NO15 (2011)№15 (2011)303424022023Copyright ©; 2011, Bionika MediaCopyright ©; 2011, ООО «Бионика Медиа»2011Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/278979

The review is devoted to the new anticoagulant drug dabigatran, a direct thrombin inhibitor. The problems of pharmacokinetics, drug and food interactions, and methods for monitoring anticoagulant effect are discussed. Effectiveness and safety of dabigatran in various clinical settings, including atrial fibrillation, are described in detail.

Обзор посвящен новому пероральному антикоагулянтному препарату дабигатран, являющемуся прямым ингибитором тромбина. Рассмотрены вопросы фармакокинетики, лекарственных и пищевых взаимодействий, способы контроля антикоагулянтного эффекта. Подробно описаны эффективность и безопасность применения дабигатрана в различных клинических ситуациях, включая мерцательную аритмию.

anticoagulantsdabigatranwarfarinatrial fibrillationантикоагулянтыдабигатранварфаринмерцательная аритмияPeterson P, Grind M, Adler J. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. J Am Coll Cardiol 2003;41:1445-51.Diener HC, and Executive Steering Committee of the SPORTIFF III and V Investigators. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies. Cerebrovasc Dis 2006;21(4):279-93.Halperin JL and Executive Steering Committee, SPORTIF III and V Study Investigators. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003;146:431-38.Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64:292-303.van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103(6):1116-27.Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005;3:103-11.Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate versus subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5:2178-85.Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361:2342-52.Wallentin L, Ezekowitz M, Simmers TA, et al. Safety and efficacy of a new oral direct thrombin inhibitor dabigatran in atrial fibrillation: a dose finding trial with comparison to warfarin. Eur Heart J 2005; 26:482.Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361(12):1139-51.Healey JS, Eikelboom J, Wallentin L, et al. Effect of age and renal function on the risks of stroke and major bleeding with dabigatran compared to warfarin: an analysis from the RE-LY study. J Am Coll Cardiol 2010;55:A4.E37.Wallentin L, Yusuf S, Ezekowitz MD, et al on behalf of the RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376(9745):975-83.Lip G, Lane D. Does Warfarin for Stroke Thromboprophylaxis Protect Against MI in Atrial Fibrillation Patients? Am J Med 2010;123:785-9.Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update onDabigatran): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;123:1144-50.